Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jon Brudvig

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Journal of Pharmaceutical Sciences|January 30, 2025
Risk assessment and management strategy of two new NDSRIs in a pharmaceutical drug product for the treatment of a rare disease: From prediction to controlPartha Mukherjee, Xin Yao, Sheela Sitaraman, et al.
Traffic (Copenhagen, Denmark)|November 11, 2021
Collagen has a unique SEC24 preference for efficient export from the endoplasmic reticulumChung-Ling Lu, Steven Ortmeier, Jon Brudvig, et al.
The Journal of Biological Chemistry|May 10, 2021
Endolysosomal N-glycan processing is critical to attain the most active form of the enzyme acid alpha-glucosidaseNithya Selvan, Nickita Mehta, Suresh Venkateswaran, et al.
Molecular Therapy. Methods & Clinical Development|March 5, 2021
Intracranial delivery of AAV9 gene therapy partially prevents retinal degeneration and visual deficits in CLN6-Batten disease miceKatherine A White, Hemanth R Nelvagal, Timothy A Poole, et al.
Frontiers in Neurology|January 20, 2025
Corrigendum: Cipaglucosidase alfa plus miglustat: linking mechanism of action to clinical outcomes in late-onset Pompe diseaseBarry J Byrne, Giancarlo Parenti, Benedikt Schoser, et al.
Frontiers in Neurology|November 4, 2024
Cipaglucosidase alfa plus miglustat: linking mechanism of action to clinical outcomes in late-onset Pompe diseaseBarry J Byrne, Giancarlo Parenti, Benedikt Schoser, et al.
Therapeutic Advances in Rare Disease|March 2, 2026
Miglustat: a first-in-class enzyme stabilizer for cipaglucosidase alfa for the treatment of late-onset Pompe diseaseRobert J Hopkin, Barry J Byrne, Mazen M Dimachkie, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Journal of Pharmaceutical Sciences|January 30, 2025
Risk assessment and management strategy of two new NDSRIs in a pharmaceutical drug product for the treatment of a rare disease: From prediction to controlPartha Mukherjee, Xin Yao, Sheela Sitaraman, et al.
Traffic (Copenhagen, Denmark)|November 11, 2021
Collagen has a unique SEC24 preference for efficient export from the endoplasmic reticulumChung-Ling Lu, Steven Ortmeier, Jon Brudvig, et al.
The Journal of Biological Chemistry|May 10, 2021
Endolysosomal N-glycan processing is critical to attain the most active form of the enzyme acid alpha-glucosidaseNithya Selvan, Nickita Mehta, Suresh Venkateswaran, et al.
Molecular Therapy. Methods & Clinical Development|March 5, 2021
Intracranial delivery of AAV9 gene therapy partially prevents retinal degeneration and visual deficits in CLN6-Batten disease miceKatherine A White, Hemanth R Nelvagal, Timothy A Poole, et al.
Frontiers in Neurology|January 20, 2025
Corrigendum: Cipaglucosidase alfa plus miglustat: linking mechanism of action to clinical outcomes in late-onset Pompe diseaseBarry J Byrne, Giancarlo Parenti, Benedikt Schoser, et al.
Frontiers in Neurology|November 4, 2024
Cipaglucosidase alfa plus miglustat: linking mechanism of action to clinical outcomes in late-onset Pompe diseaseBarry J Byrne, Giancarlo Parenti, Benedikt Schoser, et al.
Therapeutic Advances in Rare Disease|March 2, 2026
Miglustat: a first-in-class enzyme stabilizer for cipaglucosidase alfa for the treatment of late-onset Pompe diseaseRobert J Hopkin, Barry J Byrne, Mazen M Dimachkie, et al.
Pageof 1